Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA 90095, USA.
Trends Immunol. 2015 Nov;36(11):667-669. doi: 10.1016/j.it.2015.09.001. Epub 2015 Oct 1.
Recent advances in T-cell therapy for cancer, viral infections, and autoimmune diseases highlight the broad therapeutic potential of T-cell engineering. However, site-specific genetic manipulation in primary human T cells remains challenging. Two recent studies describe efficient genome editing in T cells using CRISPR and TALEN approaches.
近年来，T 细胞疗法在癌症、病毒感染和自身免疫性疾病方面的进展突出了 T 细胞工程的广泛治疗潜力。然而，对原代人 T 细胞进行定点基因操作仍然具有挑战性。最近的两项研究描述了使用 CRISPR 和 TALEN 方法在 T 细胞中进行高效基因组编辑。
